{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:36:18Z","timestamp":1760189778183,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jns.2021.117447","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T16:44:24Z","timestamp":1618677864000},"page":"117447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Tuberculosis in Myasthenia Gravis patients on immunosuppressive therapy in a high-risk area: Implications for preventative therapy"],"prefix":"10.1016","volume":"425","author":[{"given":"Elizabeth C.","family":"Steyn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan M.","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzaan","family":"Marais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannine M.","family":"Heckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"World Health Organization","key":"10.1016\/j.jns.2021.117447_bb0005"},{"issue":"4","key":"10.1016\/j.jns.2021.117447_bb0010","first-page":"406","article-title":"Changing prevalence of TB infection with increasing age in high TB burden townships in South Africa","volume":"14","author":"Wood","year":"2010","journal-title":"Int. J. Tuberc. Lung. Dis."},{"issue":"10024","key":"10.1016\/j.jns.2021.117447_bb0015","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(15)00151-8","article-title":"Tuberculosis","volume":"387","author":"Dheda","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jns.2021.117447_bb0020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S2213-2600(16)30419-2","article-title":"From latent to patent: rethinking prediction of tuberculosis","volume":"5","author":"Cobelens","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.jns.2021.117447_bb0025","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/ajt.15841","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"20","author":"Sterling","year":"2020","journal-title":"Am. J. Transplant."},{"issue":"15","key":"10.1016\/j.jns.2021.117447_bb0030","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMcp1005750","article-title":"Latent tuberculosis infection in the United States","volume":"364","author":"Horsburgh","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"97","key":"10.1016\/j.jns.2021.117447_bb0035","first-page":"1","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol."},{"issue":"6","key":"10.1016\/j.jns.2021.117447_bb0040","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/mus.25154","article-title":"Characteristics of acetylcholine-receptor-antibody\u2013negative myasthenia gravis in a south African cohort","volume":"54","author":"Huda","year":"2016","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.jns.2021.117447_bb0045","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of Thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.jns.2021.117447_bb0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.nmd.2007.07.002","article-title":"Myasthenia gravis in south Africans: racial differences in clinical manifestations","volume":"17","author":"Heckmann","year":"2007","journal-title":"Neuromuscul. Disord."},{"issue":"4","key":"10.1016\/j.jns.2021.117447_bb0055","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/mus.26172","article-title":"Myasthenic ophthalmoparesis: time to resolution after initiating immune therapies","volume":"58","author":"Europa","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2021.117447_bb0060","first-page":"16","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2021.117447_bb0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.18637\/jss.v008.i02","article-title":"Logistic regression in rare events data","volume":"8","author":"King","year":"2003","journal-title":"J. Stat. Softw."},{"issue":"6","key":"10.1016\/j.jns.2021.117447_bb0070","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.5194\/nhess-12-1937-2012","article-title":"Logistic regression applied to natural hazards: rare event logistic regression with replications","volume":"12","author":"Guns","year":"2012","journal-title":"Nat. Hazards Earth Syst. Sci."},{"issue":"4","key":"10.1016\/j.jns.2021.117447_bb0075","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1198\/106186008X384898","article-title":"Toward a common framework for statistical analysis and development","volume":"17","author":"Imai","year":"2008","journal-title":"J. Comput. Graph. Stat."},{"key":"10.1016\/j.jns.2021.117447_bb0080","series-title":"Relogit: Rare Events Logistic Regression for Dichotomous Dependent Variables, \u201cZelig Everyone\u2019s Stat. Software.\u201d","first-page":"102","author":"Choirat","year":"2013"},{"issue":"7","key":"10.1016\/j.jns.2021.117447_bb0085","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/bimj.4710350716","article-title":"Confidence intervals for the mean of a Poisson distribution: a review","volume":"35","author":"Sahai","year":"1993","journal-title":"Biom. J."},{"key":"10.1016\/j.jns.2021.117447_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2020.00775","article-title":"Management issues in myasthenia gravis patients living with HIV: a case series and literature review","volume":"11","author":"Heckmann","year":"2020","journal-title":"Front. Neurol."},{"issue":"15","key":"10.1016\/j.jns.2021.117447_bb0095","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1\u2013neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jns.2021.117447_bb0100","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.4177","article-title":"Persisting PET-CT lesion activity and M. tuberculosis mRNA after pulmonary tuberculosis cure","volume":"22","author":"Malherbe","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.jns.2021.117447_bb0105","first-page":"135","article-title":"Tuberculosis risk in persons with \u201cfibrotic\u201d x-ray lesions","volume":"47","author":"Steinbr\u00fcck","year":"1972","journal-title":"Bull. Int. Union Tuberc."},{"key":"10.1016\/j.jns.2021.117447_bb0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijid.2016.11.006","article-title":"Preventative therapy for latent tuberculosis infection- the promise and the chalennges","volume":"56","author":"Fox","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.jns.2021.117447_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/thoraxjnl-2015-207991","article-title":"What defines latent infection with Mycobacterium tuberculosis in patients with autoimmune disease?","volume":"71","author":"Sester","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jns.2021.117447_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/828939","author":"Narisimhan","year":"2013","journal-title":"Pulm. Med."},{"key":"10.1016\/j.jns.2021.117447_bb0125","doi-asserted-by":"crossref","first-page":"722","DOI":"10.5588\/ijtld.10.0284","article-title":"Polyneuropathy, anti-tuberculous treatment and the role of pyridoxine in the HIV\/AIDS era: a systematic review","volume":"15","author":"van der Watt","year":"2011","journal-title":"Int. J. Tuberc. Lung. Dis."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21001416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21001416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:54:42Z","timestamp":1758383682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21001416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":25,"alternative-id":["S0022510X21001416"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.117447","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tuberculosis in Myasthenia Gravis patients on immunosuppressive therapy in a high-risk area: Implications for preventative therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.117447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117447"}}